China Acts To Block Fatal Fake Of Diabetes Drug Brand
This article was originally published in PharmAsia News
Executive Summary
Chinese food and drug authorities have arrested four people suspected of selling lethal fake copies of Tang Zhi Ning Jiao Nang, a drug for treating diabetes. The State FDA began a national search for other evidence of the drugs after two patients died in an autonomous province. The suspect drugs were found to contain glibenclamide, masked as a drug once made by Guangxi Pingnan Pharmaceutical. The SFDA ordered medical institutions to stop using the brand for diabetes until they could be checked and to record cases where the brand was used and submit samples to local inspection agencies. (Click here for more
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.